This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berek, J. S. Articles by Nicodemus, C. F. Search for Related Content PubMed PubMed Citation Articles by Berek, J. S. Articles by Nicodemus, C. F. Social Bookmarking                            What's this?

Biologic and Immunologic Therapies for Ovarian Cancer

From the David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; AltaRex Corp, Waltham, MA; and Unither Pharmaceuticals, Inc, Wellesley Hills, MA.

Address reprint requests to Jonathan S. Berek, MD, David Geffen School of Medicine at UCLA, Division of Gynecologic Oncology, 24-137 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1740; e-mail: jberek{at}mednet.ucla.edu.

Biologic therapy of ovarian cancer has been conducted using nonspecific biologic response modifiers, cytokines, monoclonal antibodies (MAbs), vaccines, and gene therapy. Antibodies directed toward her2/neu have also been studied. Phase I and II gene therapy trials using adenoviral vectors containing a wild-type or modified p53 have shown that the treatment is well tolerated. Phase II and III trials are ongoing with MAbs directed against CA-125 (MAb B43.13) and an antibody directed against HMFG1 (anti-HMFG1–yttrium-90–labeled antibody). The trials have shown that these agents are well tolerated and that immunologic responses occur, although the ultimate clinical value of these agents remains to be determined. Prolonged survival after MAb B43.13 treatment has been correlated with changes in several immune parameters, including human antimurine antibody, Ab₂, anti–CA-125 antibody development, and induced T-cell immunity. Clinical trials using a MAb directed toward the encoded products of her2/neu have shown minimal activity against ovarian cancer in a phase I and II trial conducted by the Gynecologic Oncology Group. Cytokine therapies have been administered systemically and intraperitoneally. Intracavitary interferon alfa, interferon gamma, and interleukin-2 alone or in combination with cytotoxic therapy in phase I and II trials demonstrated intraperitoneal lymphoid cell stimulation and produced antitumor responses. A randomized trial of chemotherapy with or without interferon gamma in primary treatment produced a response and a progression-free survival advantage in the arm that incorporated the interferon gamma, without a statistically significant benefit in overall survival. A phase III study of interferon gamma in combination with first-line chemotherapy is currently ongoing.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Berek, P. T. Taylor, A. Gordon, M. J. Cunningham, N. Finkler, J. Orr Jr, S. Rivkin, B. C. Schultes, T. L. Whiteside, and C. F. Nicodemus Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer J. Clin. Oncol., September 1, 2004; 22(17): 3507 - 3516. [Abstract] [Full Text] [PDF]